版本:
中国

BRIEF-Ultragenyx initiates phase 3 study of UX007 in patients with disabling movement disorders

April 27 Ultragenyx Pharmaceutical Inc:

* Ultragenyx initiates global phase 3 study of UX007 in GLUT1 DS patients with disabling movement disorders Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐